Topic: checkpoint inhibitors
Investors worried last year that Merck couldn’t replicate its Keytruda-chemo combo success in a phase 3 trial. But it just did.
BMS’s Opdivo is the only immuno-oncology drug approved to treat kidney cancer, but more rivals are threatening that status.
Chinese pharmaceutical database PharmCube highlighted 16 possible blockbuster approvals in China in 2018.
Pfizer has long expected I-O rivals to push aside kidney cancer med Sutent. But now, it’s getting in on the action.
If you thought 2017 was a game-changer for immuno-oncology, just wait.
If 2016 was the year immuno-oncology first stopped looking invincible, 2017 was the year trial misses became more commonplace.
Merck’s Keytruda boasts an FDA approval in third-line stomach cancer, but its ambitions for moving earlier into treatment just took a hit.
Merck’s quest to move Keytruda further into blood cancers hit a snag over the summer, but now, it’s back on track.
More results are out from a trial of Roche’s Tecentriq in lung cancer, but industry watchers still don’t have many of the answers they’re looking for.
On Thursday, Roche unveiled positive results from its first-line lung-cancer combo trial—but those results raised more questions than they provided answers.